arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Insight Molecular Diagnostics Inc.

IMDX
$4.82 ▼ -0.03 (-0.62%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
47 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Bullish
auto_awesome

Analytical Summary

Insight Molecular Diagnostics Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $166.4M
Dividend Yield
Revenue Growth -98.5%
Op. Margin None
ROIC 32.6%
FCF / Share $-0.24
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.00K
↓ -98.5%
Net Income Profit after all expenses
$-4.29M
↑ +35.7%
Operating Margin Operating profit as % of sales
-318.0%
↑ +23.2%
FCF / Share Free cash flow per share
$-0.24
— +0.4%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
6
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters